Decoy Therapeutics Inc. (DCOY)
NASDAQ: DCOY · Real-Time Price · USD
3.280
-0.130 (-3.81%)
At close: Aug 20, 2026, 4:00 PM EDT
3.100
-0.180 (-5.49%)
After-hours: Aug 20, 2026, 7:07 PM EDT
Decoy Therapeutics Revenue
Decoy Therapeutics had revenue of $227.63K in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $227.63K.
Revenue (ttm)
$227.63K
Revenue Growth
n/a
P/S Ratio
10.13
Revenue / Employee
$20,694
Employees
11
Market Cap
2.15M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 1.84M | -3.39M | -64.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| HCW Biologics | 6.72M |
| PMGC Holdings | 2.58M |
| Onconetix | 645.82K |
| Jupiter Neurosciences | 64.69K |
| Virax Biolabs Group | 12.42K |
DCOY News
- 8 days ago - Decoy Therapeutics Quarterly report: Q2 2026 - Filings
- 16 days ago - Decoy Therapeutics Proxy statement: Proxy filing - Filings
- 16 days ago - Decoy Therapeutics Proxy statement: Proxy filing - Filings
- 17 days ago - Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform - PRNewsWire
- 24 days ago - Decoy Therapeutics’ D-MAV platform shows inhibition of Ebola Zaire virus - TheFly
- 24 days ago - Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats - PRNewsWire
- 27 days ago - Decoy Therapeutics Proxy statement: Proxy filing - Filings
- 5 weeks ago - Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors - PRNewsWire